An oral protease inhibitor for the treatment of hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

If you have a Hayes login, click here to view the full report on the Knowledge Center.